Rituximab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06244368CT.gov GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | — | Recruiting | — | — | — |
NCT05821192CT.gov Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | — | Unknown | — | — | — |
NCT02535247CT.gov Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01805037CT.gov Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | — | Terminated | — | — | — |
NCT01644253CT.gov Phase 1b Safety and Efficacy Study of TRU-016 | — | Terminated | — | — | — |
NCT01482962CT.gov Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01445535CT.gov Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB · 64 |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →